SCHEMBL32665417

SCHEMBL32665417

Clc1cccc(-c2nnc3ccc(Cl)nn23)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK3 O43781 2/20 0.58
CCNT1 O60563 2/20 0.58
CCNA2 P20248 2/20 0.58
CDK2 P24941 2/20 0.58
CDK9 P50750 2/20 0.58
CDK5 Q00535 2/20 0.58
DYRK1A Q13627 2/20 0.58
CDK5R1 Q15078 2/20 0.58
DYRK2 Q92630 2/20 0.58
DYRK1B Q9Y463 2/20 0.58
LRRK2 Q5S007 2/20 0.55
KDM4E B2RXH2 5/20 0.50
ALDH1A1 P00352 3/20 0.50
SMN1; SMN2 Q16637 3/20 0.50
HIF1A Q16665 1/20 0.50
HSD17B10 Q99714 3/20 0.47
HPGD P15428 2/20 0.47
LMNA P02545 1/20 0.47
MAPT P10636 1/20 0.47
ALOX15 P16050 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24401671 0.88 DPP4 (0.54) LRRK2KDM4EALDH1A1SMN1; SMN2HSD17B10
SCHEMBL29617977 0.88 DPP4 (0.54) LRRK2KDM4EALDH1A1SMN1; SMN2HSD17B10
SCHEMBL15365501 0.85 KDM4E (0.65) DYRK3CCNT1CCNA2CDK2CDK9
SCHEMBL12874554 0.85 DYRK3 (0.60) DYRK3CCNT1CCNA2CDK2CDK9
SCHEMBL4784567 0.83 BRD4 (0.65) CDK2DYRK1ADYRK1BLRRK2KDM4E
SCHEMBL15365361 0.81 PIM1 (0.62) CDK2DYRK1ALRRK2KDM4EALDH1A1
SCHEMBL5620191 0.81 GRK5 (0.46) DYRK3CCNT1CCNA2CDK2CDK9
SCHEMBL937211 0.81 KDM4E (0.44) DYRK3CCNT1CCNA2CDK2CDK9
SCHEMBL32664904 0.81 CDK2 (0.63) CCNA2CDK2CDK5DYRK1ACDK5R1
SCHEMBL32665401 0.81 PIM1 (0.62) CDK2DYRK1ALRRK2KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260022124-A1 THERAPEUTIC COMPOUNDS AND METHODS UNIV MINNESOTA (US) 2026-01-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260022124-A1 THERAPEUTIC COMPOUNDS AND METHODS NR5A1, CYP17A1, CNR1 DYRK3 4480/4885CCNT1 435/4885CCNA2 1087/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.